Stephens Inc. AR Increases Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Stephens Inc. AR increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 6,116 shares of the medical equipment provider’s stock after acquiring an additional 202 shares during the quarter. Stephens Inc. AR’s holdings in Zimmer Biomet were worth $646,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ZBH. Equity Investment Corp purchased a new stake in Zimmer Biomet in the 3rd quarter worth about $70,104,000. Hotchkis & Wiley Capital Management LLC increased its holdings in Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after acquiring an additional 577,320 shares during the last quarter. Van ECK Associates Corp boosted its stake in Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares during the period. Thompson Siegel & Walmsley LLC bought a new position in Zimmer Biomet in the 3rd quarter worth about $41,588,000. Finally, FMR LLC boosted its stake in Zimmer Biomet by 27.6% in the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after purchasing an additional 162,384 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on ZBH shares. Truist Financial restated a “hold” rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Wells Fargo & Company raised their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Barclays cut their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $100.52 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70. The business’s 50 day simple moving average is $106.49 and its two-hundred day simple moving average is $107.79. The stock has a market capitalization of $20.01 billion, a P/E ratio of 22.59, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company posted $2.20 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.96%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.